



Page 1 of 3

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re application : Henrik Jernstedt et al.
Serial No. : 10/576.777

Serial No. : 10/576,777 Filed : April 21, 2006

For : ANDROGEN RECEPTOR MODULATORS

Examiner : Attorney Docket : 102870-102

Group Art Unit

Confirmation No.

Customer No. : 27267

I hereby certify that this correspondence is being deposited with the United States Postal Service, First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents,

P.O. Box 1450, Alexandria, VA 22313-1450 on 25 May 2006

By Tody E. Jh. Todd E. Garabedian, Ph.D.

Registration No. 39,197
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.56, the Examiner is respectfully requested to consider the references cited on attached Form PTO-1449. A copy of each reference (if not previously submitted) is enclosed. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

[X] 1. This Information Disclosure Statement is being filed within three months of the U. S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

- 2. This Information Disclosure Statement is being filed more than three months after the U. S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
 - a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1); and no fee is required under 37 C.F.R. §1.17(p).
 - [] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2); and no fee is required under 37 C.F.R. §1.17(p).
 - [] Please charge Deposit Account No. <u>23-1665</u> in the amount of \$180.00 in payment of the fee under 37 C.F.R. \$1.17(p). Two additional copies of this Information Disclosure Statement are enclosed.
 - A check in the amount of \$180.00 is attached hereto in payment of the fee under 37 C.F.R. \$1.17(p).
- [·] 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered.
 - a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. \$1.97(e)(1).

- [] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- Please charge Deposit Account No. <u>23-1665</u> in the amount of \$130.00 in payment of the fee under 37 C.F.R. §1.17(i)(1). Two additional copies of this Information Disclosure Statement are enclosed.
- A check in the amount of \$130.00 is attached hereto in payment of the fee under 37 C.F.R. \$1.17(i)(1).

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. \$1.56(b).

Respectfully submitted,

HENRIK JERNSTEDT, ET AL.

Date: 25 May 2006

Todd E. Garabedian, Ph.D.

Registration No. 39,197 Attorney for Applicants

WIGGIN AND DANA LLP One Century Tower

New Haven, CT 06508-1832

Telephone: (203) 498-4400 Telecopier: (203) 782-2889

FORM PTO-1449

INFORMATION DISCLOSURE AND APPLICANT WAY 9-0 2006			ATTY. DOCKE	ATTY. DOCKET NO. 102870-102 SERIAL NO. 10/576,777		10/576,777
			APPLICANT: HENRIK JERNSTEDT, ET AL.			
			FILING DATE: APRIL 21, 2006		GROUP:	
10	\$/		U.S. PATENT DOCL	IMENTS		
EXAMINADEN INITIAL	NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPR.
	4.723,986	02/09/1988				
57.E.		FC	REIGN PATENT DO	CUMENTS		
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION Yes No
	WO 01/58854 A1	08/16/2001		C07C	237/22	Yes
	WO 02/016310 A1	02/28/2002		C07C	233/15	Yes
	EP 0797980	10/01/1997				
	EP 0488756					
	JP 49020129					
	l					
	DATABASE US (KELLER	CA 'Online! C	CHEMICAL AR	ILE, DATE, PERTINEN BSTRACTS SERV lative hair dye cor ctober 1997 (1992)	VICE, COLUM	
	US (HASHIZ	UME, KAZU	JNAR ET AL.):	BSTRACTS SER "Oxidative colo , 3 June 1992 (19	r-producing reas	
		EUGENE G	.): "Herbicidal	STRACTS SER' oxazolidines and		
	US (SUDA, I 1974 (1974-0	HIDEAKI ET 2-22).	AL.): "p-Nitro	STRACTS SER' aniline derivative	s", XP00232058	7, 22 February
	US (ZORINA	A, L. N. ET A	L.): "New appr	STRACTS SER' oach to the synth 2320588 (1989).		

considered. Include copy of this form with next communication to applicant.